logo

Companies Race to Develop Coronavirus drug

2 / 9
Abbvie
Abbvie

On January 27, 2020, the Chinese health authorities requested the supply of AbbVie’s (ABBV) fixed-dose HIV drug Kaletra, also known as Aluvia, to treat pneumonia caused by the new coronavirus COVID-19.

In response to the request, AbbVie donated Aluvia as an experimental option to support the fight against the deadly virus.

A controlled trial of Aluvia to treat COVID-19 is underway in China.

ABBV has traded in a range of $62.66 to $97.86 in the last 1 year. The stock closed Wednesday’s (Feb.26, 2020) trading at $88.41, down 0.86%.